Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 52-58 , January 2010

Diagnosis and Natural History of HIV-Associated Nephropathy

  • Mohamed G. Atta

      Affiliations

    • Corresponding Author InformationAddress correspondence to Mohamed G. Atta, MD, MPH, 1830 East Monument Street, Suite 416, Baltimore, MD 21287.

References 

  1. Gardenswartz MH, Lerner CW, Seligson GR, et al. Renal disease in patients with AIDS: A clinicopathologic study. Clin Nephrol. 1984;21:197–204
  2. Pardo V, Aldana M, Colton RM, et al. Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med. 1984;101:429–434
  3. Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med. 1984;310:669–673
  4. Mazbar SA, Schoenfeld PY, Humphreys MH. Renal involvement in patients infected with HIV: Experience at San Francisco General Hospital. Kidney Int. 1990;37:1325–1332
  5. Ross MJ, Klotman PE. Recent progress in HIV-associated nephropathy. J Am Soc Nephrol. 2002;13:2997–3004
  6. Carbone L, D'Agati V, Cheng JT, et al. Course and prognosis of human immunodeficiency virus-associated nephropathy. Am J Med. 1989;87:389–395
  7. Cantor ES, Kimmel PL, Bosch JP. Effect of race on expression of acquired immunodeficiency syndrome-associated nephropathy. Arch Intern Med. 1991;151:125–128
  8. Laradi A, Mallet A, Beaufils H, et al. HIV-associated nephropathy: outcome and prognosis factors. Groupe d' Etudes Nephrologiques d'Ile de France. J Am Soc Nephrol. 1998;9:2327–2335
  9. Williams DI, Williams DJ, Williams IG, et al. Presentation, pathology, and outcome of HIV associated renal disease in a specialist centre for HIV/AIDS. Sex Transm Infect. 1998;74:179–184
  10. Abbott KC, Hypolite I, Welch PG, et al. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: Patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol. 2001;14:377–383
  11. Kopp JB, Winkler C. HIV-associated nephropathy in African Americans. Kidney Int Suppl. 2003;83:S43–S49
  12. Eggers PW, Kimmel PL. Is there an epidemic of HIV Infection in the US ESRD program?. J Am Soc Nephrol. 2004;15:2477–2485
  13. Shahinian V, Rajaraman S, Borucki M, et al. Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am J Kidney Dis. 2000;35:884–888
  14. Nochy D, Glotz D, Dosquet P, et al. Renal disease associated with HIV infection: A multicentric study of 60 patients from Paris hospitals. Nephrol Dial Transplant. 1993;8:11–19
  15. Nochy D, Glotz D, Dosquet P, et al. Renal lesions associated with human immunodeficiency virus infection: North American vs. European experience. Adv Nephrol Necker Hosp. 1993;22:269–286
  16. Lucas GM, Mehta SH, Atta MG, et al. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS. 2007;21:2435–2443
  17. Bruggeman LA, Ross MD, Tanji N, et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol. 2000;11:2079–2087
  18. Gharavi AG, Ahmad T, Wong RD, et al. Mapping a locus for susceptibility to HIV-1-associated nephropathy to mouse chromosome 3. Proc Natl Acad Sci U S A. 2004;101:2488–2493
  19. Papeta N, Chan KT, Prakash S, et al. Susceptibility loci for murine HIV-associated nephropathy encode trans-regulators of podocyte gene expression. J Clin Invest. 2009;119:1178–1188
  20. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40:1175–1184
  21. Winston JA, Bruggeman LA, Ross MD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med. 2001;344:1979–1984
  22. Szabo S, James CW, Telford G. Unusual presentations of primary human immunodeficiency virus infection. AIDS Patient Care STDS. 2002;16:251–254
  23. Izzedine H, Wirden M, Launay-Vacher V. Viral load and HIV-associated nephropathy. N Engl J Med. 2005;353:1072–1074
  24. Estrella M, Fine DM, Gallant JE, et al. HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis. 2006;43:377–380
  25. Zhong J, Zuo Y, Ma J, et al. Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy. Kidney Int. 2005;68:1048–1060
  26. He JC, Husain M, Sunamoto M, et al. Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J Clin Invest. 2004;114:643–651
  27. Hanna Z, Kay DG, Rebai N, et al. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell. 1998;95:163–175
  28. Hanna Z, Kay DG, Cool M, et al. Transgenic mice expressing human immunodeficiency virus type 1 in immune cells develop a severe AIDS-like disease. J Virol. 1998;72:121–132
  29. Zuo Y, Matsusaka T, Zhong J, et al. HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis. J Am Soc Nephrol. 2006;17:2832–2843
  30. Marras D, Bruggeman LA, Gao F, et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med. 2002;8:522–526
  31. Lu T-C, He JC, Wang Z-H, et al. HIV-1 nef disrupts the podocyte actin cytoskeleton by interacting with diaphanous interacting protein. J Biol Chem. 2008;283:8173–8182
  32. Conaldi PG, Bottelli A, Baj A, et al. Human immunodeficiency virus-1 tat induces hyperproliferation and dysregulation of renal glomerular epithelial cells. Am J Pathol. 2002;161:53–61
  33. Wali RK, Drachenberg CI, Papadimitriou JC, et al. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet. 1998;352:783–784
  34. Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: A 12-year cohort study. AIDS. 2004;18:541–546
  35. Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant. 2006;21:2809–2813
  36. Scialla JJ, Atta MG, Fine DM. Relapse of HIV-associated nephropathy after discontinuing highly active antiretroviral therapy. AIDS. 2007;21:263–264
  37. Winston JA, Klotman ME, Klotman PE. HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. Kidney Int. 1999;55:1036–1040
  38. Levin ML, Palella F, Shah S, et al. HIV-associated nephropathy occurring before HIV antibody seroconversion. Am J Kidney Dis. 2001;37:E39
  39. Ross MJ, Klotman PE, Winston JA. HIV-associated nephropathy: Case study and review of the literature. AIDS Patient Care STDS. 2000;14:637–645
  40. Berliner AR, Fine DM, Lucas GM, et al. Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol. 2008;28:478–486
  41. Han TM, Naicker S, Ramdial PK, et al. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int. 2006;69:2243–2250
  42. D'Agati V, Suh JI, Carbone L, et al. Pathology of HIV-associated nephropathy: A detailed morphologic and comparative study. Kidney Int. 1989;35:1358–1370
  43. D'Agati V, Appel GB. HIV infection and the kidney. J Am Soc Nephrol. 1997;8:138–152
  44. Albaqumi M, Soos TJ, Barisoni L, et al. Collapsing glomerulopathy. J Am Soc Nephrol. 2006;17:2854–2863
  45. Post FA, Campbell LJ, Hamzah L, et al. Predictors of renal outcome in HIV-associated nephropathy. Clin Infect Dis. 2008;46:1282–1289
  46. Atta MG, Longenecker JC, Fine DM, et al. Sonography as a predictor of human immunodeficiency virus-associated nephropathy. J Ultrasound Med. 2004;23:603–610
  47. Atta MG, Choi MJ, Longenecker JC, et al. Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy. Am J Med. 2005;118:1288.e1221–1288.e1226
  48. Eustace JA, Nuermberger E, Choi M, et al. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int. 2000;58:1253–1260
  49. Burns GC, Paul SK, Toth IR, et al. Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol. 1997;8:1140–1146
  50. Smith MC, Austen JL, Carey JT, et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med. 1996;101:41–48
  51. Briggs WA, Tanawattanacharoen S, Choi MJ, et al. Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy. Am J Kidney Dis. 1996;28:618–621
  52. Burns GC, Matute R, Onyema D, et al. Response to inhibition of angiotensin-converting enzyme in human immunodeficiency virus-associated nephropathy: A case report. Am J Kidney Dis. 1994;23:441–443
  53. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555–570
  54. He JC, Lu TC, Fleet M, et al. Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway. J Am Soc Nephrol. 2007;18:93–102
  55. Available at: http://www.hivtransplant.com/. Accessed May 28, 2009
  56. Rao TK, Friedman EA, Nicastri AD. The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med. 1987;316:1062–1068
  57. Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004;66:1145–1152
  58. Ortiz C, Meneses R, Jaffe D, et al. Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. Kidney Int. 1988;34:248–253
  59. Tebben JA, Rigsby MO, Selwyn PA, et al. Outcome of HIV infected patients on continuous ambulatory peritoneal dialysis. Kidney Int. 1993;44:191–198
  60. Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol. 2002;13:1889–1893
  61. Macrae J, Friedman AL, Eggers P, et al. Improved survival in HIV-infected African-Americans with ESRD. Clin Nephrol. 2005;64:124–128
  62. Atta MG, Fine DM, Kirk GD, et al. Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland. Clin Infect Dis. 2007;45:1625–1632
  63. US Renal Data System (USRDS): 2006 Annual Data Report: National Institutes of Health, National Institute of Diabetes and Digestive Diseases and Kidney Diseases, Bethesda, MD. http://www.usrds.org Accessed January 8, 2008
  64. Ahuja TS, Borucki M, Funtanilla M, et al. Is the prevalence of HIV-associated nephropathy decreasing?. Am J Nephrol. 1999;19:655–659

PII: S1548-5595(09)00164-5

doi: 10.1053/j.ackd.2009.08.005

Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 52-58 , January 2010

Article Tools

* Image Usage & Resolution